Back to News
Market Impact: 0.15
Galderma Nemluvio Data Show Durable Skin And Itch Benefits Through 3 Years
Source: Nasdaq
Healthcare & Biotech
Galderma will present new long-term data for Nemluvio in patients with moderate-to-severe atopic dermatitis and prurigo nodularis at the 2026 Fall Clinical Dermatology Conference in Las Vegas, October 8–11. The article provides no data results or further detail on the findings.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GALD0.20
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures